Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Bone and Mineral Metabolism
Published in: Journal of Bone and Mineral Metabolism 6/2020

01-11-2020 | Osteoporosis | Original Article

LncRNA LOXL1-AS1 controls osteogenic and adipocytic differentiation of bone marrow mesenchymal stem cells in postmenopausal osteoporosis through regulating the miR-196a-5p/Hmga2 axis

Authors: Ling Zhang, Haiqin Xie, Shiliang Li

Published in: Journal of Bone and Mineral Metabolism | Issue 6/2020

Login to get access

Abstract

Introduction

Exploring molecular mechanisms of human bone marrow mesenchymal stem cells (hBMMSCs) differentiation, a crucial step for bone formation, is a new direction for treating postmenopausal osteoporosis. LncRNAs are involved in lots of biological processes including hBMMSCs differentiation. The present study aimed to explore the effect of LOXL1-AS1 on hBMMSCs differentiation.

Materials and methods

We examined the expression levels of LOXL1-AS1, miR-196a-5p and Hmga2 in peripheral blood from postmenopausal osteoporosis patients by RT-qPCR, and detected their changes during the osteogenic differentiation of hBMMSCs by RT-qPCR. RT-qPCR and western blot measured the level of biomarkers of bone formation and osteogenic differentiation (osteopontin, OPN; Alkaline phosphatase, ALP; Runt-related transcription factor-2, Runx-2). The effects of LOXL1-AS1 on the osteogenic and adipocytic differentiation of hBMMSCs were, respectively, determined by ALP, ARS staining assays and oil red O staining assay.

Results

The abnormal high expression of LOXL1-AS1 was found in patients. LOXL1-AS1 expression showed a gradual decrease during the osteogenic differentiation of hBMMSCs. However, LOXL1-AS1 overexpression inhibited the hBMMSCs osteogenic differentiation but promoted adipocytic differentiation. Furthermore, LOXL1-AS1 was identified to be a sponge of miR-196a-5p and Hmga2 as a target gene of miR-196a-5p. Besides, LOXL1-AS1 sponged miR-196a-5p to mediate Hmga2 expression, which played contrary effects on regulating osteogenic and adipocytic differentiation of hBMMSCs. Moreover, LOXL1-AS1/miR-196a-5p/Hmga2 axis regulated hBMMSCs differentiation through controlling C/EBPβ-mediated PPARγ expression.

Conclusion

These findings facilitate understanding the molecular mechanism of hBMMSCs differentiation and bring up a novel sight for postmenopausal osteoporosis therapy.
Appendix
Available only for authorised users
Literature
1.
2.
Xu J, Lombardi G, Jiao W, Banfi G (2016) Effects of exercise on bone status in female subjects, from young girls to postmenopausal women: an overview of systematic reviews and meta-analyses. Sports Med (Auckl, NZ) 46:1165–1182CrossRef
3.
Eastell R, O'Neill TW, Hofbauer LC, Langdahl B, Reid IR, Gold DT, Cummings SR (2016) Postmenopausal osteoporosis. Nat Rev Dis Primers 2:16069CrossRefPubMed
4.
Wang C, Meng H, Wang X, Zhao C, Peng J, Wang Y (2016) Differentiation of bone marrow mesenchymal stem cells in osteoblasts and adipocytes and its role in treatment of osteoporosis. Med Sci Monit 22:226–233CrossRefPubMedPubMedCentral
5.
Aghebati-Maleki L, Dolati S, Zandi R, Fotouhi A, Ahmadi M, Aghebati A, Nouri M, Kazem Shakouri S, Yousefi M (2019) Prospect of mesenchymal stem cells in therapy of osteoporosis: a review. J Cell Physiol 234:8570–8578CrossRefPubMed
6.
Qi M, Zhang L, Ma Y, Shuai Y, Li L, Luo K, Liu W, Jin Y (2017) Autophagy maintains the function of bone marrow mesenchymal stem cells to prevent estrogen deficiency-induced osteoporosis. Theranostics 7:4498–4516CrossRefPubMedPubMedCentral
7.
Hu L, Yin C, Zhao F, Ali A, Ma J, Qian A (2018) Mesenchymal stem cells: cell fate decision to osteoblast or adipocyte and application in osteoporosis treatment. Int J Mol Sci 19:360CrossRefPubMedCentral
8.
Wu Y, Xie L, Wang M, Xiong Q, Guo Y, Liang Y, Li J, Sheng R, Deng P, Wang Y, Zheng R, Jiang Y, Ye L, Chen Q, Zhou X, Lin S, Yuan Q (2018) Mettl3-mediated m(6)A RNA methylation regulates the fate of bone marrow mesenchymal stem cells and osteoporosis. Nat Commun 9:4772CrossRefPubMedPubMedCentral
9.
10.
11.
Zhou Q, An Y, Tang Y (2019) Long noncoding RNA-regulator of reprogramming alleviates hypoxia-induced cerebral injury in mice model and human via modulating apoptosis complexes. J Integr Neurosci 18:431–437CrossRefPubMed
12.
Pan J, Fang S, Tian H, Zhou C, Zhao X, Tian H, He J, Shen W, Meng X, Jin X, Gong Z (2020) lncRNA JPX/miR-33a-5p/Twist1 axis regulates tumorigenesis and metastasis of lung cancer by activating Wnt/beta-catenin signaling. Mol Cancer 19:9CrossRefPubMedPubMedCentral
13.
Gao GC, Yang DW, Liu W (2020) LncRNA TERC alleviates the progression of osteoporosis by absorbing miRNA-217 to upregulate RUNX2. Eur Rev Med Pharmacol Sci 24:526–534PubMed
14.
Bai T, Liu Y, Li B (2019) LncRNA LOXL1-AS1/miR-let-7a-5p/EGFR-related pathway regulates the doxorubicin resistance of prostate cancer DU-145 cells. IUBMB Life 71:1537–1551CrossRefPubMed
15.
Long B, Li N, Xu XX, Li XX, Xu XJ, Liu JY, Wu ZH (2018) Long noncoding RNA LOXL1-AS1 regulates prostate cancer cell proliferation and cell cycle progression through miR-541-3p and CCND1. Biochem Biophys Res Commun 505:561–568CrossRefPubMed
16.
Wang H, Li L, Yin L (2018) Silencing LncRNA LOXL1-AS1 attenuates mesenchymal characteristics of glioblastoma via NF-kappaB pathway. Biochem Biophys Res Commun 500:518–524CrossRefPubMed
17.
Chen S, Li W, Guo A (2019) LOXL1-AS1 predicts poor prognosis and promotes cell proliferation, migration, and invasion in osteosarcoma. Biosci Rep 39:4
18.
Xiao X, Ren J, Chen J, Liu Z, Tian Y, Nabar NR, Wang M, Hao L (2018) LOX-related collagen crosslink changes act as an initiator of bone fragility in a ZDF rats model. Biochem Biophys Res Commun 495:821–827CrossRefPubMed
19.
Dong HT, Liu Q, Zhao T, Yao F, Xu Y, Chen B, Wu Y, Zheng X, Jin F, Li J, Xing P (2019) Long non-coding RNA LOXL1-AS1 drives breast cancer invasion and metastasis by antagonizing miR-708-5p expression and activity. Mol Ther Nucl Acids 19:696–705CrossRef
20.
Styrkarsdottir U, Stefansson OA, Gunnarsdottir K, Thorleifsson G, Lund SH et al (2019) GWAS of bone size yields twelve loci that also affect height, BMD, osteoarthritis or fractures. Nat Commun 10:2054CrossRefPubMedPubMedCentral
21.
Xi Y, Shen W, Ma L, Zhao M, Zheng J, Bu S, Hino S, Nakao M (2016) HMGA2 promotes adipogenesis by activating C/EBPβ-mediated expression of PPARγ. Biochem Biophys Res Commun 472:617–623CrossRefPubMed
22.
Xu C, Wang J, Zhu T, Shen Y, Tang X, Fang L, Xu Y (2016) Cross-talking between PPAR and WNT signaling and its regulation in mesenchymal stem cell differentiation. Curr Stem Cell Res Ther 11:247–254CrossRefPubMed
23.
Hauser MA, Aboobakar IF, Liu Y, Miura S, Whigham BT et al (2015) Genetic variants and cellular stressors associated with exfoliation syndrome modulate promoter activity of a lncRNA within the LOXL1 locus. Hum Mol Genet 24:6552–6563CrossRefPubMedPubMedCentral
24.
Wrobel E, Leszczynska J, Brzoska E (2016) The characteristics of human bone-derived cells (HBDCS) during osteogenesis in vitro. Cell Mol Biol Lett 21:26CrossRefPubMedPubMedCentral
25.
Zhu Y, Wang Y, Jia Y, Xu J, Chai Y (2019) Catalpol promotes the osteogenic differentiation of bone marrow mesenchymal stem cells via the Wnt/beta-catenin pathway. Stem Cell Res Ther 10:37CrossRefPubMedPubMedCentral
26.
Zhou Q, Zhu L, Zhang D, Li N, Li Q, Dai P, Mao Y, Li X, Ma J, Huang S (2016) Oxidative stress-related biomarkers in postmenopausal osteoporosis: a systematic review and meta-analyses. Dis Markers 2016:7067984CrossRefPubMedPubMedCentral
27.
Thu HE, Mohamed IN, Hussain Z, Shuid AN (2018) Exploring molecular mechanism of bone-forming capacity of Eurycoma longifolia: evidence of enhanced expression of bone-related biomarkers. J Ayurveda Integr Med 9:272–280CrossRefPubMed
28.
29.
Maruyama T, Nishihara K, Umikawa M, Arasaki A, Nakasone T, Nimura F, Matayoshi A, Takei K, Nakachi S, Kariya KI, Yoshimi N (2018) MicroRNA-196a-5p is a potential prognostic marker of delayed lymph node metastasis in early-stage tongue squamous cell carcinoma. Oncol Lett 15:2349–2363PubMed
30.
31.
Zhong F, Zhang W, Cao Y, Wen Q, Cao Y, Lou B, Li J, Shi W, Liu Y, Luo R, Chen C (2018) LncRNA NEAT1 promotes colorectal cancer cell proliferation and migration via regulating glial cell-derived neurotrophic factor by sponging miR-196a-5p. Acta Biochim Biophys Sin 50:1190–1199CrossRefPubMed
32.
Morishita A, Zaidi MR, Mitoro A, Sankarasharma D, Szabolcs M, Okada Y, D'Armiento J, Chada K (2013) HMGA2 is a driver of tumor metastasis. Can Res 73:4289–4299CrossRef
33.
Zhang S, Mo Q, Wang X (2019) Oncological role of HMGA2 (Review). Int J Oncol 55:775–788PubMed
34.
35.
Wei J, Li H, Wang S, Li T, Fan J, Liang X, Li J, Han Q, Zhu L, Fan L, Zhao RC (2014) let-7 enhances osteogenesis and bone formation while repressing adipogenesis of human stromal/mesenchymal stem cells by regulating HMGA2. Stem Cells Dev 23:1452–1463CrossRefPubMedPubMedCentral
36.
Zhang Y, Liu Y, Wu M, Wang H, Wu L, Xu B, Zhou W, Fan X, Shao J, Yang T (2020) MicroRNA-664a-5p promotes osteogenic differentiation of human bone marrow-derived mesenchymal stem cells by directly downregulating HMGA2. Biochem Biophys Res Commun 521:9–14CrossRefPubMed
37.
Farmer SR (2005) (2005) Regulation of PPARgamma activity during adipogenesis. Int J Obes 29:S13–16CrossRef
38.
Sun H, Kim JK, Mortensen R, Mutyaba LP, Hankenson KD, Krebsbach PH (2013) Osteoblast-targeted suppression of PPARγ increases osteogenesis through activation of mTOR signaling. Stem Cells (Dayt, Ohio) 31:2183–2192CrossRef
39.
Kang S, Bennett CN, Gerin I, Rapp LA, Hankenson KD, Macdougald OA (2007) Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma. J Biol Chem 282:14515–14524CrossRefPubMed
Metadata
Title
LncRNA LOXL1-AS1 controls osteogenic and adipocytic differentiation of bone marrow mesenchymal stem cells in postmenopausal osteoporosis through regulating the miR-196a-5p/Hmga2 axis
Authors
Ling Zhang
Haiqin Xie
Shiliang Li
Publication date
01-11-2020
Publisher
Springer Singapore
Published in
Journal of Bone and Mineral Metabolism / Issue 6/2020
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-020-01123-z

Other articles of this Issue 6/2020

Journal of Bone and Mineral Metabolism 6/2020 Go to the issue

Perspective

Executive summary of clinical practice guide on fracture risk in lifestyle diseases

Original Article

Fracture risk assessment in an Italian group of transgender women after gender-confirming surgery

Original Article

Maternal pre-pregnancy underweight is associated with underweight and low bone mass in school-aged children

Review Article

Protective role of osteocalcin in diabetes pathogenesis

Original Article

Efficacy of denosumab co-administered with vitamin D and Ca by baseline vitamin D status

Announcement

Journal of Bone and Mineral Metabolism Best Paper Award 2020
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits